Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.

Enrollment in the ongoing 澳洲幸运5官方开奖结果体彩网:Phase 2 trial of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU), or chܫronic hives, was paused "following t🍃he observation of certain in vivo preclinical toxicology findings."

In vivo toxicology is the study of the effect of the toxicity of a drug on a live organism, usually an animal.

Incyte Says It Won't Develop Drug To Treat Intense Itching

It also said data from the Phase 2 study of MRGPRX4 (INCB000547) to treat cholestatic pruritus (CP), a liver disorder that causes intense itching, "does not support further development."

Incyte said it had shared the data with the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) and will work with the agency toꦯ "determi▨ne next steps."

The company's stock recently was down more than 13%. It is up about 6% this year.